Overall and disease-specific survival of Hodgkin lymphoma survivors who subsequently developed gastrointestinal cancer
Autor: | Josée M. Zijlstra, Otto Visser, Gustaaf W. van Imhoff, Judith M. Roesink, Michael Schaapveld, Monique E. van Leerdam, Philip Poortmans, Augustinus D.G. Krol, Petur Snaebjornsson, Pieternella J. Lugtenburg, Cecile P.M. Janus, Richard W.M. van der Maazen, Max Beijert, Berthe M.P. Aleman, Lisanne S. Rigter, Flora E. van Leeuwen, Anna M. van Eggermond |
---|---|
Přispěvatelé: | Hematology, CCA - Cancer Treatment and quality of life, Radiation Oncology |
Rok vydání: | 2018 |
Předmět: |
Male
0301 basic medicine Cancer Research Colorectal cancer medicine.medical_treatment Gastroenterology 0302 clinical medicine Cancer Survivors Interquartile range Non-U.S. Gov't Gastrointestinal Neoplasms Original Research RISK Research Support Non-U.S. Gov't Hazard ratio second malignancy Middle Aged Hodgkin Disease 2ND MALIGNANT NEOPLASMS Women's cancers Radboud Institute for Health Sciences [Radboudumc 17] Oncology Radiology Nuclear Medicine and imaging 030220 oncology & carcinogenesis Cohort population characteristics Female Rare cancers Radboud Institute for Health Sciences [Radboudumc 9] RADIOTHERAPY Adult medicine.medical_specialty gastrointestinal cancer Research Support survival Young Adult 03 medical and health sciences SDG 3 - Good Health and Well-being Internal medicine parasitic diseases Journal Article medicine Humans Radiology Nuclear Medicine and imaging Gastrointestinal cancer Chemotherapy CHILDHOOD-CANCER business.industry Clinical Cancer Research LONG-TERM SURVIVAL Cancer social sciences medicine.disease Survival Analysis Radiation therapy 030104 developmental biology business human activities Hodgkin lymphoma |
Zdroj: | Cancer Medicine, 8(1), 190-199 Cancer Medicine, 8, 190-199 Cancer Medicine, 8(1), 190-199. John Wiley and Sons Ltd Cancer Medicine, 8(1), 190-199. John Wiley & Sons Ltd. Cancer Medicine Cancer Medicine, 8, 1, pp. 190-199 Cancer medicine, 8(1), 190-199. Wiley Cancer Medicine, 8(1), 190. John Wiley and Sons Ltd Rigter, L S, Schaapveld, M, Janus, C P M, Krol, A D G, van der Maazen, R W M, Roesink, J, Zijlstra, J M, van Imhoff, G W, Poortmans, P M P, Beijert, M, Lugtenburg, P J, Visser, O, Snaebjornsson, P, van Eggermond, A M, Aleman, B M P, van Leeuwen, F E & van Leerdam, M E 2019, ' Overall and disease-specific survival of Hodgkin lymphoma survivors who subsequently developed gastrointestinal cancer ', Cancer Medicine, vol. 8, no. 1, pp. 190-199 . https://doi.org/10.1002/cam4.1922 |
ISSN: | 2045-7634 |
Popis: | Contains fulltext : 203188.pdf (Publisher’s version ) (Open Access) BACKGROUND: Hodgkin lymphoma (HL) survivors have an increased risk of gastrointestinal (GI) cancer. This study aims to evaluate whether survival of patients who survived HL and developed GI cancer differs from survival of first primary GI cancer patients. METHODS: Overall and cause-specific survival of GI cancer patients in a HL survivor cohort (GI-HL, N = 104, including esophageal, gastric, small intestinal, and colorectal cancer) was compared with survival of a first primary GI cancer patient cohort (GI-1, N = 1025, generated by case matching based on tumor site, gender, age, and year of diagnosis). Cox proportional hazards regression was used for survival analyses. Multivariable analyses were adjusted for GI cancer stage, grade of differentiation, surgery, radiotherapy, and chemotherapy. RESULTS: GI-HL cancers were diagnosed at a median age of 54 years (interquartile range 45-60). No differences in tumor stage or frequency of surgery were found. GI-HL patients less often received radiotherapy (8% vs 23% in GI-1 patients, P < 0.001) and chemotherapy (28% vs 41%, P = 0.01) for their GI tumor. Compared with GI-1 patients, overall and disease-specific survival of GI-HL patients was worse (univariable hazard ratio (HR) 1.30, 95% confidence interval (CI) 1.03-1.65, P = 0.03; and HR 1.29, 95% CI 1.00-1.67, P = 0.049, respectively; multivariable HR 1.33, 95% CI 1.05-1.68, P = 0.02; and HR 1.33, 95% CI 1.03-1.72, P = 0.03, respectively). CONCLUSIONS: Long-term overall and disease-specific survival of GI cancer in HL survivors is worse compared with first primary GI cancer patients. Differences in tumor stage, grade of differentiation, or treatment could not explain this worse survival. |
Databáze: | OpenAIRE |
Externí odkaz: |